Given the selective expression of PD-L1 on LECs, but not other cell types in LNs, the reduction of PD-L1+ SCS floor LEC subsets and the accumulation of PD-L1− LEC subsets in metastatic LNs may significantly impact the efficacy of immune checkpoint therapy, such as anti-PD-L1 agents like atezolizumab and durvalumab, in cancer patients. The gene discussed is CD274; the disease is cancer.